Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Isr J Health Policy Res ; 12(1): 1, 2023 01 26.
Article in English | MEDLINE | ID: mdl-36698178

ABSTRACT

BACKGROUND: As opioid prescription in Israel is increasing, there is a growing need for monitoring opioid use disorder and providing opioid agonist therapy. Our goal is to describe, sub-analyze, and identify obstacles in the treatment of opioid misuse in the Israeli medication assisted treatment centers. METHODS: Data on methadone, buprenorphine, and buprenorphine combined with naloxone for the indication of opioid addiction treatment for the period 2013-2020 were obtained from pharmaceutical companies that distribute them in Israel. Data on utilization of these drugs were also extracted from the database maintained by the Israel Ministry of Health's Pharmaceutical Administration Division. The data were converted to defined daily doses (DDD)/1000 inhabitants/day. RESULTS: The number of patients receiving medication assisted treatment increased by 10% since 2013, with a shift from buprenorphine alone to buprenorphine/naloxone in government-run centers. Methadone remains the most popular maintenance drug. CONCLUSIONS: The change in opioid maintenance prescription does not match the significant increase in opioid consumption. Optimization of treatment can be achieved by the creation of a comprehensive database, cooperation between healthcare organizations and the government and further development of non-stigmatic and accessible services.


Subject(s)
Buprenorphine , Opioid-Related Disorders , Humans , Analgesics, Opioid/therapeutic use , Israel , Buprenorphine/therapeutic use , Opioid-Related Disorders/drug therapy , Methadone/therapeutic use , Naloxone/therapeutic use , Pharmaceutical Preparations
2.
J Voice ; 37(3): 433-439, 2023 May.
Article in English | MEDLINE | ID: mdl-33750623

ABSTRACT

OBJECTIVES: Expression of mu-opioid receptors (MORs) has not been investigated in head and neck cancer. In this study, we aimed to assess the expression of opioids receptors in laryngeal cancer, compared to adjacent non-malignant tissue. STUDY DESIGN: A retrospective case series in a single academic center. METHODS: Sixty-four specimens were taken from 32 matched patients, diagnosed with laryngeal-carcinoma (20 supraglottic and 12 glottic), and were analyzed using immunohistochemical stains for MOR. All sections were examined and evaluated with a semi-quantitative analysis for staining intensity and cell count for a percentage of the positively stained cells. Survival of patients was compared based on MOR expression. RESULTS: MOR staining intensity was significantly increased in laryngeal-carcinoma compared to the normal tissue adjacent to the carcinoma (P = 0.019). The percentage of stained cells in non-involved supraglottis was significantly higher compared to the non-involved glottis (P = 0.022), yet this difference was no longer found between supra- and glottic-carcinoma tissues. CONCLUSION: MOR may play a role in the laryngeal cancer environment, as the expression in tumor cells alters from adjacent non-cancerous tissue.


Subject(s)
Carcinoma, Squamous Cell , Head and Neck Neoplasms , Laryngeal Neoplasms , Larynx , Humans , Laryngeal Neoplasms/pathology , Retrospective Studies , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/pathology , Larynx/pathology , Glottis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...